These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38039716)

  • 1. MCC950 alleviates seizure severity and angiogenesis by inhibiting NLRP3/ IL-1β signaling pathway-mediated pyroptosis in mouse model of epilepsy.
    Hong Y; Wei C; Fu M; Li X; Zhang H; Yao B
    Int Immunopharmacol; 2024 Jan; 126():111236. PubMed ID: 38039716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the NLRP3 inflammasome reduces brain edema and regulates the distribution of aquaporin-4 after cerebral ischaemia-reperfusion.
    Wang H; Chen H; Jin J; Liu Q; Zhong D; Li G
    Life Sci; 2020 Jun; 251():117638. PubMed ID: 32251636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
    Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
    Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages.
    Zeng W; Wu D; Sun Y; Suo Y; Yu Q; Zeng M; Gao Q; Yu B; Jiang X; Wang Y
    Sci Rep; 2021 Sep; 11(1):19305. PubMed ID: 34588488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis.
    Zhang L; Jiang YH; Fan C; Zhang Q; Jiang YH; Li Y; Xue YT
    Biomed Pharmacother; 2021 Nov; 143():112133. PubMed ID: 34474337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
    Qu J; Yuan Z; Wang G; Wang X; Li K
    Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
    Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Huang S; Chen Z; Fan B; Chen Y; Zhou L; Jiang B; Long H; Zhong W; Li X; Li Y
    J Neuroimmunol; 2021 May; 354():577543. PubMed ID: 33714750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
    Zhang W; Ba G; Tang R; Li M; Lin H
    Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propionibacterium acnes induces intervertebral disc degeneration by promoting nucleus pulposus cell pyroptosis via NLRP3-dependent pathway.
    He D; Zhou M; Bai Z; Wen Y; Shen J; Hu Z
    Biochem Biophys Res Commun; 2020 Jun; 526(3):772-779. PubMed ID: 32265028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
    Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
    Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCC950 Inhibits NLRP3 Inflammasome and Alleviates Axonal Injures in Early Stages of Diffuse Axonal Injury in Rats.
    Zhao J; Guo X; Wang B; Yang Z; Huang T; Guo D; Zhang M; Song J
    Neurochem Res; 2020 Sep; 45(9):2020-2031. PubMed ID: 32474832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice.
    Dempsey C; Rubio Araiz A; Bryson KJ; Finucane O; Larkin C; Mills EL; Robertson AAB; Cooper MA; O'Neill LAJ; Lynch MA
    Brain Behav Immun; 2017 Mar; 61():306-316. PubMed ID: 28003153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation.
    Zhao M; Zhang J; Xu Y; Liu J; Ye J; Wang Z; Ye D; Feng Y; Xu S; Pan W; Wang M; Wan J
    Int Immunopharmacol; 2021 Oct; 99():108046. PubMed ID: 34435581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCC950 attenuates inflammation-mediated damage in canines with Staphylococcus pseudintermedius keratitis by inhibiting the NLRP3 inflammasome.
    Guo L; Wang Z; Li J; Cui L; Dong J; Meng X; Zhu G; Li J; Wang H
    Int Immunopharmacol; 2022 Jul; 108():108857. PubMed ID: 35597123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of combination of anakinra and MCC950 against acute lung injury is achieved through suppression of the NF-κB-mediated-MAPK and NLRP3-caspase pathways.
    Wang X; Chen S; Zhao L; Shi X
    Int Immunopharmacol; 2021 Aug; 97():107506. PubMed ID: 34022766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
    Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
    Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model.
    He W; Long T; Pan Q; Zhang S; Zhang Y; Zhang D; Qin G; Chen L; Zhou J
    J Neuroinflammation; 2019 Apr; 16(1):78. PubMed ID: 30971286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.